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Chronic Experimental Autoimmune Encephalomyelitis (EAE) was induced in rats to evaluate a new drug 
candidate (GEMSP) for the treatment of multiple sclerosis. This work is a part of preclinical studies on GEMSP, 
which is made up of fatty acids, vitamins and amino acids or their derivatives; all these compounds were linked 
to Poly-L-Lysine. In order to evaluate the effects of GEMSP, animals were divided into three experimental 
groups: 1) EAE rats treated with GEMSP; 2) EAE rats treated with NaCl; and 3) non-EAE rats. Using 
immunocytochemical techniques with a pan-leukocyte marker (anti-CD 45), differential leukocyte infiltration 
was compared in the central nervous systems of the different experimental groups. Antibodies directed against a 
component of GEMSP, the conjugated methionine, were used in all three groups. We found that: 1) GEMSP was 
effective in abolishing EAE. The crises and clinical scores were completely abolished in the animals of the first 
group, but not in the animals belonging to the second group; 2) the degree of leukocyte infiltration varied, 
depending on the different EAE stages, but was not related to the clinical score; and 3) after using anti-conjugated 
methionine antibodies, we observed immunoreactivity only in the motoneurons of the ventral horn of the spinal 
cord in the animals of the first group. This immunoreactivity was not found in the animals of the second or third 
groups. No methionine immunoreactivity was found in the brain. Our results suggest that GEMSP may be a 
potential drug candidate against the pathogenic processes involved in multiple sclerosis, inhibiting EAE episodes 
and brain leukocyte infiltration. Our results also show that one component of GEMSP, the methionine 
compound, is stored inside motoneurons. The possible physiological actions of GEMSP on spinal cord 
motoneurons are discussed. 
Key words: EAE-MS, leukocyte infiltration, CD 45, spinal cord motoneurons, conjugated methionine, immunocytochemistry. 
Introduction 
Multiple Sclerosis (MS) is a chronic and 
progressive inflammatory autoimmune disease of the 
central nervous system (CNS) whose aetiology 
remains unknown. During the course of the disease, 
patients present focal leukocyte infiltration, which 
produces inflammation followed by demyelization 
and, as the disease progresses, patients develop 
increasing handicaps. However, currently tested and 
approved drugs for the medical treatment of MS have 
failed to change the course of the illness. In addition, 
such drugs elicit well-reported side effects [1]. 
Experimental autoimmune encephalomyelitis 
(EAE) is an autoimmune inflammatory disease of the 
rodent CNS that is widely used for the evaluation of 
different drugs (β interferon (IFN- β), glatiramer 
acetate (GA), laquinimod, and linomide) [2-7]. Among 
the multiple possibilities and variations, there are two 
classical models of EAE: a) acute EAE, characterized 
by a clear EAE crisis accompanied by inflammation of 
the CNS, with a relatively short duration and nearly 
complete recovery of the animals (see [8]); and b) 
chronic EAE, in which the animals present clinical 
signs for at least two months with several EAE crises, 
and in general, they remain with a handicap; a sign of 
irreversible damage to the CNS. The main advantages 
of this latter model are that it appears to mimic the 
pathogenesis of MS; the disease changes over long 
periods of time; and no recovery of the clinical signs 
appears due to the demyelization processes.  
Brain leukocyte infiltration is related to 
inflammation, and has previously been evaluated in 
EAE models in which animals were treated with 
different drugs: IFN-β [3, 6, 9], Laquinimod [5], 
Linomide [10] or dexamethasone [11]. Currently Int. J. Biol. Sci. 2008, 4 
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approved therapies (IFN-β and GA) are assumed to 
exert their effects on the Th1/Th2 phenotype ratio of 
T-cells [12], although MS inflammatory lesions do not 
predict later changes in impairment or disability [13]. 
This means that treatment focused exclusively on 
inflammation is not appropriate, and this should 
encourage the scientific community to search for new 
perspectives and new treatments for MS.  
In an acute EAE model, we previously presented 
the drug studied here, designated GEMSP, as a new 
candidate for MS treatment. In that acute model, 
GEMSP inhibited both the EAE episode and brain 
leukocyte infiltration [8]. However, despite the 
demonstrated beneficial effects of GEMSP in the acute 
animal model of EAE, to date the presence of the drug 
in the rat central nervous system has not been 
confirmed. Moreover, no studies have been carried out 
on the actions of GEMSP in chronic EAE models. To 
date, no side effects have been reported for GEMSP 
either in an open clinical trial or in experimental 
animals, since GEMSP does elicits neither biological or 
haematological nor hepatic side effects [8]. It should be 
noted that GEMSP (used in the animal models) and 
GEMSEP1, used in the clinical trial, do not have 
different components, and were designated thus only 
in order to differentiate between the data obtained in 
animal models and in clinical trials. 
Thus, using a chronic EAE model [14], 
characterized by a long-term disease and currently 
accepted by the scientific community, the aims of the 
present study were to test the effects of GEMSP on 
EAE episodes and CNS leukocyte infiltration, as well 
as to demonstrate that some components of GEMSP 
are stored inside neurons.  
MATERIALS AND METHODS 
Animals  
Thirty-one Lewis 1A female rats aged 10-11 
weeks (weight around 190 g) obtained from CERJ 
Janvier (France) were used in this study. The animals 
were kept under standardized light and temperature 
conditions and had free access to food and water. They 
remained in their cages for at least two weeks before 
the experiments (day 14, D -14) (see Figure 1). 
Induction of EAE 
Chronic EAE induction was performed on day 0 
(D0, see experimental procedure, depicted in Figure 1) 
in groups 1 and 2 (see below). Each rat from these 
groups was immunized with a 250 µl-solution 
containing: 50 µg of myelin oligodendrocyte 
glycoprotein (MOG), produced and purified at the 
laboratory of Professor Villoslada (Pamplona, Spain) 
(see [15]), and complete Freund's adjuvant (ACF), 
purchased from Sigma, to which 200 µg of 
heat-inactivated  Mycobacterium tuberculosis 
H37RA  (Difco) had been added. The rats were 
anaesthetized with isofluorane and the solution was 
once injected intradermally at the base of the tail. 
 
 
 
FIGURE 1. Experimental procedure. The main experimental 
processes are represented in this figure for a better appreciation 
of the timing of each manipulation (induction, beginning of 
treatment, and perfusions). D: days; D -14: arrival date of the 
animals; D0: date of model induction; D9: start of treatment; 
D15, D24, D60 and D100: days on which animals were 
perfused. 
 
Animal Groups and Clinical Evaluation of EAE 
Two groups of animals were immunized on D0: 
1) EAE-immunized rats treated with GEMSP (n = 10) 
and 2) EAE-immunized rats treated with NaCl (n = 18). 
A third group of animals was not immunized 
(non-EAE-immunized rats treated with NaCl) (control) 
(n = 3). The study, using the three groups, was 
repeated twice (first experiment, n = 14; second 
experiment, n = 17) and the same batches of GEMSP 
a n d  M O G  w e r e  u s e d  i n  b o t h  c a s e s .  W e  f o u n d  n o  
difference between the first and second experiments. 
The animals were weighed and scored according 
to a previously described scale [14] 6 days/week 
throughout the experiments by two alternating 
investigators. The neurological signs of EAE, which 
started around day fifteen after its induction (D15, see 
Figure 1), were assessed and scored using the 
following scale: 0, no signs; 1, tail weakness or tail 
paralysis; 2, hind leg paraparesis or hemiparesis; 3, 
hind leg paralysis or hemiparalysis; 4, complete 
paralysis (tetraplegy). 
Treatment of the animals began nine days after 
the induction of chronic EAE (D9, see Figure 1). All 
animals received a single daily subcutaneous injection 
of their respective solution after D9. Thus, the animals 
in group 1 were treated with 7.5 mg of GEMSP per day 
(dissolved in 0.5 ml of a NaCl solution) and the 
animals in groups 2 and 3 received 0.5 ml of a NaCl 
solution per day. The experimental design, protocols, 
and procedures used in this work were performed 
under the guidelines of the ethics and legal 
recommendations of Spanish, French, and European 
legislation. This work was also approved by the 
Bioethics Committee of the University of Salamanca 
(Spain). Int. J. Biol. Sci. 2008, 4 
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Synthesis of the Drug Candidate and 
Immunocytochemistry 
GEMSP was synthesized according to patent 
numbers 6114388 (USA) and 792167 (EU). This drug is 
a functional polycomplex in which different 
compounds are linked to Poly-L-Lysine via 
glutaraldehyde, glutaric anhydride, or amide bonds 
(see [8]). The different families of components included 
in GEMSP had different properties and concentrations. 
The concentrations of each component are detailed in 
Table 1. 
TABLE 1. GEMSP constituents. Different families of 
GEMSP constituents with the respective concentration of each 
compound in the solution used for treating the animals. This 
treatment took place under identical conditions throughout the 
experiments, using the same lot number. Lyophilised GEMSP 
was reconstituted with purified water before subcutaneous 
injection. AA: amino acids; M: molarity; PL: Poly-L.Lysine 
Families of   
Compounds 
Different Constituents of 
GEMSP Linked to PL 
Final 
Concentration 
of GEMSP 
(M) 
Azelaic Acid - PL - Oleic Acid  1.00E-03 
Azelaic Acid - PL - Palmitoleic 
Acid 
1.00E-03 
T-T-Farnesyl-L.Cysteine - PL - 
Oleic Acid 
1.00E-03 
Oleic Acid - PL - Palmitic Acid  1.00E-03 
Oleic Acid - PL - Myristic Acid  1.00E-03 
Oleic Acid - PL - Linoleic Acid  1.00E-03 
Oleic Acid - PL - Thioctic Acid  2.00E-04 
Cholesterol -PL - Oleic Acid  1.00E-03 
Linoleic Acid - PL  1.00E-03 
Oleic Acid - PL - Palmitoleic 
Acid 
1.00E-03 
Fatty Acids 
T-T-Farnesyl-L.Cysteine - PL - 
Palmitic Acid 
2.00E-04 
α-Tocopherol-succinate - PL  2.00E-04  Antioxidants 
Ascorbic Acid - PL  2.00E-04 
L.Methionine - Reduced 
Glutaraldehyde - PL 
2.00E-04 
L.Cysteine - Reduced 
Glutaraldehyde - PL 
2.00E-04 
Taurine - Reduced 
Glutaraldehyde - PL 
2.00E-04 
Histamine - Glutaric 
Anhydride - PL 
4.00E-04 
L.Histidine - Glutaric 
Anhydride - PL 
4.00E-04 
AA and Derivatives 
5-Methoxytryptamine - 
Glutaric Anhydride - PL 
4.00E-04 
Immunocytochemistry 
The animals were deeply anaesthetized with 
urethane (1 g/kg, intraperitoneal), heparinized, and 
perfused via the ascending aorta with 50-100 ml of cold 
physiologic saline (0.9% NaCl) and with 500 ml of cold 
4% paraformaldehyde in 0.1 M phosphate-buffer (PB), 
pH 7.2 (10 min). Perfusions were carried out on 
different days (D15, D24, D60 and D100; see Figure 1) 
to check the evolution of CNS leukocyte infiltration. 
After perfusion, the CNS was dissected out and 
processed as previously described for 
immunocytochemistry (see [8, 16-18]). In order to 
avoid possible interference with endogenous 
peroxidase, free-floating sections were pre-treated 
with a solution containing methanol and H2O2 (2/1) 
for 30 min [8, 16-19]. Then, the sections were washed 
for 30 min (at room temperature, “RT”) in 0.15 M PB 
saline (PBS) (pH 7.2), after which they were 
pre-incubated for 30 min (RT) in PBS containing 10% of 
normal horse serum and 0.3% of Triton X-100 (PBSt). 
The sections were then incubated overnight at 4ºC in 
PBSt containing monoclonal anti-rat CD 45 antiserum 
(purchased from Serotec or Pharmingen and diluted 
1/500) to demonstrate leukocyte infiltration and 
anti-rabbit conjugated methionine antiserum 
(purchased from Gemacbio, France, and diluted 
1/1,000) to demonstrate GEMSP. Sections were then 
washed in PBS (30 min, RT), incubated for 1 h (RT) 
with biotinylated anti-mouse or anti-rabbit 
immunogammaglobulin (Vector and Serotec), diluted 
1/200 in PBSt, and washed with PBS (30 min) at RT. 
Following this, sections were incubated for 1 h (RT) 
with 1/100 diluted avidin-biotin-peroxidase complex 
(Vectas`tain) in PBSt. The sections were then washed 
again in PBS for 30 min (RT) and Tris-HCl buffer (pH 
7.6) (10 min; RT). Tissue-bound peroxidase was 
developed with H2O2 using 3, 3’ diaminobenzidine as 
chromogen. The sections were then rinsed with PBS 
and coverslipped with PBS/Glycerol (1/1). 
The specificity of the tissue immunoreactivity has 
already been tested for antibodies directed against CD 
45 (see [8]). As previously reported, identical results 
were obtained after application of the 
immunocytochemical technique using the anti-CD 45 
purchased from Pharmingen and Serotec (see [8]). 
Antibodies directed against the conjugated methionine 
were obtained after several immunizations with the 
methionine-glutaraldehyde (G)-bovine serum albumin 
(BSA) immunogen (250 µg) in a solution of complete or 
incomplete Freund’s adjuvant (0.5 ml) and NaCl (9 
g/l) (0.5 ml). The serum obtained was preabsorbed 
with (BSA-G) and purified. Regarding the specificity of 
the anti-conjugated methionine antiserum, the 
following histological controls were carried out: a) 
omission of the primary antiserum in the first 
incubation bath; and b) preabsorption of the 
anti-conjugated methionine antibody with conjugated 
methionine  (300  μg of methionine-G-BSA per ml of 
diluted antiserum) or with methionine-G-PL (300 µg of 
GEMSP per ml of diluted antiserum). No residual 
immunoreactivity was found in any case. In addition, 
the absence of immunoreactivity for conjugated Int. J. Biol. Sci. 2008, 4 
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methionine in animals not treated with GEMSP 
(second and third groups) and the presence of such 
immunoreactivity in animals of the first group (rats 
treated with GEMSP) also indicated the specificity of 
the immunoreactivity. The ELISA tests carried out 
revealed that the signal observed in the tissue was 
specific for conjugated methionine (see Table 2, taken 
from the data sheet of Gemacbio Laboratories). 
TABLE 2. Using competition ELISA tests (data obtained from 
the data sheet of GEMACBIO), cross-reactivity was calculated 
from the displacement curves at half-displacement: the best 
recognized was methionine-Gc, whose concentration was 
divided by the concentration of each of the other conjugates. Gc: 
conjugated via glutaraldehyde.  
Compound Cross-reactivity  ratio 
L. Methionine-Gc  1 
       Homocysteine-Gc  1/>1,000 
        Homocysteic acid-Gc  1/>10,000 
        Cystathionine-Gc  1/>10,000 
L. Cysteine-Gc  1/>10,000 
        L. Glutamate-Gc  1/>10,000 
Image Processing 
Finally, the stereotaxic atlas of Paxinos and 
Watson [20] was used for nomenclature and mapping. 
P h o t o m i c r o g r a p h s  w e r e  o b t a i n e d  w i t h  a n  O l y m p u s  
DP-50-CU digital camera attached to a Leica 
microscope. To improve the visualization of the 
results, only the brightness and contrast of the images 
were adjusted, with no further manipulation of the 
photographs. 
RESULTS 
Two parameters were evaluated to study the 
efficacy of the GEMSP  in a chronic EAE model: the 
abolition of EAE crises and brain leukocyte infiltration 
as a signal of inflammation.   
Clinical Score 
Several factors must be taken into account when 
using EAE models. Among them, one important point 
is the clinical score of the animals and their evolution. 
In our study, the animals were weighed and observed 
daily (six days a week) by different researchers to 
preserve objectivity. Three animals included in group 
2 (EAE-immunized rats treated with NaCl) did not 
develop EAE correctly. These animals were excluded 
from the data analysis since no leukocyte infiltration 
was found, hence corroborating the absence of a 
clinical score. The remaining animals belonging to 
group 2 had a specific profile, since the immunological 
response found in each animal was individual and 
specific to it (for examples, see Figure 2). Accordingly, 
in view of the considerable variability between 
animals, we classified the rats in the second group into 
three subgroups according to their clinical signs.  
 
 
FIGURE 2. Different clinical types. The clinical  types 
observed during the EAE episodes are represented in this figure 
by three different examples of evolution. These three profiles 
can be considered to be representative of the clinical stages 
observed in animals, and can be classified into three subgroups 
within the group 2 (EAE-immunized rats treated with NaCl). n: 
number of animals. Note that the clinical score of experimental 
groups 1 and 3 was always 0 (not shown). 
 Int. J. Biol. Sci. 2008, 4 
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Figure 2 offers examples of three different 
subgroups of animals with very different clinical 
patterns (the number of animals showing a similar 
pattern is indicated). 
Neither the animals in group 1 (EAE-immunized 
rats treated with GEMSP) nor those in group 3 
(non-EAE-immunized rats treated with NaCl) (control) 
showed clinical signs. This means that none of the 
animals in either group developed EAE (Figure 3). 
This was expected in group 3 because the animals had 
not been subjected to EAE induction. However, the 
group 1 animals were induced with the same solution 
as the group 2 animals, indicating that the absence of 
EAE in group 1 must been due to the GEMSP 
treatment.  
CD 45 (pan-leukocyte marker) 
Group 1: EAE animals treated with GEMSP 
The results found for this marker in group 1 were 
in accordance with those previously published in the 
acute EAE model (see [8]), since in general an absence 
of brain leukocyte infiltration, or only a very low level, 
was observed in this group (see Figures 4A and 5A and 
Table 3). 
 
TABLE 3. Distribution of brain leukocyte infiltrates in the 
experimental groups. Leukocyte infiltration visualized with 
the panleukocyte marker (CD 45) in several brain levels and the 
spinal cord. -: absence of leukocytes; +: low density of 
leukocytes; +++: high density of leukocytes; B: Bregma level 
corresponding to the stereotaxic atlas of Paxinos and Watson 
(1982); CNS: Central Nervous System; S: scarce distribution 
(only in some regions); W: widespread distribution in different 
regions of the level marked.*: region not studied in this 
experiment. 
 GROUP 
 
EAE RATS treated with NaCl
 
 
 
CNS 
LEVEL 
 
EAE 
RATS 
treated 
with 
GEMSP 
 
NON-EAE 
RATS 
treated with 
NaCl 
 
D 15  D 24 D 60  D 
100 
B - 0.2 to B 
- 0.3 
- -  +++/W  +/W -  - 
B - 0.3 to B 
- 0.8 
- -  +++/W  +/W +/S  - 
B - 1.3  - -  +++/W  *  +/S  - 
B - 2.8  +/S -  +++/W  +/W -  - 
B - 3.3  - -  +++/W  *  -  - 
B - 3.3 to B 
- 3.8 
+/S -  +++/W  *  -  - 
B - 10.8  - -  +++/W  +/W -  - 
B - 11.3 to 
B - 11.8 
- -  +++/W  +/W   - 
B - 14.3  - -  +++/W  +/W -  +/S
Spinal 
Cord 
- -  *  *  +/S  or 
+++/S
+/S
 
 
 
FIGURE 3. Mean clinical scores of the experimental groups (1, 2 and 3). Squares indicate the values of the animals belonging to 
experimental groups 1 and 3 (clinical score: 0). Note that only animals of group 2 (x) had a clinical score. In the inserted table, the 
mean clinical score (score) and the standard deviation (SD) are also represented for the three experimental groups at different dates. Int. J. Biol. Sci. 2008, 4 
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FIGURE 4. Brain leukocyte infiltration in the three experimental groups. Absence of infiltration (anti-CD 45) in the group treated 
with GEMSP (Group 1) (A) and in the control group (Group 3) (B); C: representative section belonging to animals of group 2 
perfused sixty days after induction (D60, see Figure 1); D: section of an animal of group 2 perfused twenty-four days after induction 
(D24, see Figure 1). Note the marked differences in the infiltration shown in figures 3C (D60) and D (D24); images of the same 
group showing differences in the process, depending on the perfusion date. 
 
FIGURE 5. Examples of brain and spinal cord leukocyte infiltration visualized with the anti-CD 45 marker. A: Image of the 
GEMSP group (Group 1), with the absence of leukocyte infiltration in the septum; B: widespread leukocyte infiltration in the septum 
of group 2 (in the first phases D15-24); C: representative image of group 3 (control: non-EAE + NaCl) at spinal cord level, with the 
absence of leukocyte infiltrates; D: Low-power image of the spinal cord of group 2; E: image of the spinal cord of animals belonging 
to group 2, at a different level than the image shown in picture D. Note that the infiltrates are much more widespread at this level (E) 
than at the level shown in D (both pictures belong to animals perfused on D60).  Int. J. Biol. Sci. 2008, 4 
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Group 2: EAE animals treated with NaCl 
We observed that the animals in the first stages of 
the EAE episode (around two weeks after 
immunization, D15, and three-four weeks after 
immunization, D24) (see Figure 1) had developed 
widespread and strong leukocyte infiltration in the 
CNS (Figures 4D, 5B, and Table 3); this infiltration was 
even higher than that previously described in the acute 
EAE model [8]. However, in later stages (D60 and 
D100) (see Figure 1) leukocyte infiltration decreased, 
although the clinical signs persisted (see Figures 2, 4C 
and Table 3). Thus, as may be seen in Figure 2, the 
clinical signs still remained after a fairly long period of 
time. This suggests that the degree of infiltration was 
not correlated with the clinical signs, since the degree 
of infiltration in the animals of group 2 differed, 
depending on the different stages (see Figures 4C, D, 
and Table 3). Similar data have been reported 
previously for the acute EAE 
model [8]. Only some animals 
continued to display a low 
leukocyte infiltration in 
certain localized regions at 
D60 (see Table 3), especially in 
lower brain levels and the 
spinal cord (see Figure 5D and 
E). 
Group 3: control 
No brain leukocyte 
infiltration was found in the 
animals of group 3 (see 
Figures 4B, 5C and Table 3). 
GEMSP in the central 
nervous system 
Following application of 
the anti-conjugated methionine antibody, we observed 
immunoreactivity in the motoneurons located in layer 
IX of the ventral horn along the whole spinal cord of 
the animals belonging to group 1 (treated with 
GEMSP) (Figure 6A, B). However, in this first group, 
after carrying out the immunocytochemical 
histological controls (preabsorption of the first 
antibody (Figure 6C) and elimination of the first 
antibody (Figure 6D)), in both cases we failed to 
observe immunoreactivity in those neurons. In 
addition, in these ventral horn motoneurons of the rat 
spinal cord we did not observe any immunoreactivity 
towards conjugated methionine in the animals of 
either the second (Figure 6E) or the third (control, 
Figure 6F) experimental groups. In both latter groups, 
the animals were not treated with GEMSP. Finally, it 
should be noted that in the brain we did not observe 
immunoreactivity towards GEMSP in any of the 
animals belonging to the three experimental groups. 
 
 
FIGURE 6. Immunoreactivity for 
GEMSP. Immunoreactivity located 
in the ventral horn motoneurons of 
the rat spinal cord was visualized 
only in the animals treated with 
GEMSP (A and B, first group). The 
immunoreactivity disappeared in 
animals of the first group when 
preabsorption (C) and elimination 
(D) of the first antibody 
(anti-conjugated methionine) were 
carried out. Immunoreactivity was 
absent in the animals of the second 
(EAE + NaCl) (E) and third groups 
(control: non-EAE + NaCl) (F). 
 Int. J. Biol. Sci. 2008, 4 
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DISCUSSION 
Here, we report for the first time that GEMSP 
abolishes the development of chronic EAE; that the 
GEMSP is stored inside nerve cells, and that, in a 
chronic model of EAE, GEMSP abolishes brain 
leukocyte infiltration.  
Effects of the GEMSP dose on EAE 
It has previously been reported [8] that the 
administration of low doses (0.75 mg per day) of 
GEMSP reduces brain leukocyte infiltration to a 
considerable extent, although no effect against the 
development of EAE was observed at such a dose. In 
order to determine the lowest dose with the maximum 
effect, we carried out a dose-range study in acute and 
chronic EAE models to determine whether there were 
other effective doses that might abolish EAE crises 
(unpublished data). The results of those experiments 
showed that the dose used here (7.5 mg per day) seems 
to be the most effective for abolishing acute and 
chronic EAE episodes. In this sense, we observed that 
there was a true dose-range effect on EAE clinical 
attack, since lower doses (3.75 mg per day) were not as 
effective in abolishing EAE crises, and doses of 0.75 
mg/day and 1.875 mg/day were not effective at all 
against EAE crise (see [8]). At a dose of 3.75 mg, 
GEMSP seems to exert a strong reduction of EAE 
episodes, although not a complete abolition in the 
acute EAE model. Here, we used a dose ten times 
higher (7.5 mg) than in the previous study [8] to see 
whether GEMSP completely abolishes the EAE process 
or not. The results reported here show for the first time 
that long-term treatment with GEMSP completely 
abolishes the development of EAE in a chronic model 
of the disease. 
Effects of GEMSP on Brain Leukocyte Infiltration 
and Clinical Scores  
As mentioned above, brain leukocyte infiltration 
related to inflammation has previously been evaluated 
using different drugs in an EAE model [3, 5, 6, 8-11]. 
However, only the study by Mangas et al. [8] reported 
the action of GEMSP and offered details about the 
neuroanatomical distribution of brain leukocyte 
infiltration, although in that study no data on 
demyelization were provided because the 
investigation was carried out in an acute EAE model. 
In both acute and chronic EAE models, the induced 
animals exhibited a very strong degree of leukocyte 
infiltration throughout their brains. The animals with 
acute EAE perfused at the peak of the EAE episode 
displayed a pronounced and widespread brain 
leukocyte infiltration [8]. This observation was similar 
to the results seen in animals with chronic EAE 
perfused at the peak of the first EAE clinical attack or 
episode. The first EAE clinical attack in the chronic 
EAE model was comparable to the peak of acute EAE, 
since the degree of leukocyte infiltration was similar. 
T h u s ,  b o t h  m o d e l s  r e v e a l e d  v e r y  s t r o n g  a n d  
widespread brain infiltration, although leukocyte 
infiltration seemed to be h i g h e r  a t  t h i s  s t a g e   (first 
clinical attack) in chronic EAE in comparison with 
previously reported data found for acute EAE.  
Previously published data have shown that the 
administration of GEMSP (0.75 mg per day) is 
sufficient to significantly decrease brain leukocyte 
infiltration, even though the EAE episode is not 
modified with this low dose of GEMSP [8]. In the 
present work, after the administration of GEMSP (7.5 
mg per day) to animals in which a chronic model of 
EAE was developed the dose was also effective against 
leukocyte brain infiltration. 
As mentioned in the Results section, our data 
clearly show that there was no correlation between the 
clinical score and leukocyte infiltration, these data are 
in accordance with previously published results for 
acute EAE [8]. In the present work, we observed the 
crucial importance of leukocyte infiltration during the 
first stages on EAE, a mechanism that could play a 
secondary role in ensuing stages, as occurs in MS. This 
is very important for establishing the efficiency of 
current therapies for MS. Such therapies are focused 
on immunomodulation (GA and IFN-β), and such 
drugs only treat this aspect of the disease. 
The variable clinical signs in each animal 
belonging to group 2 (EAE animals treated with NaCl), 
as well as the score and evolution of the disease in the 
animals of the same group, indicates the complexity of 
this chronic EAE model. Figure 2 shows the different 
rat profiles. The variability observed in this chronic 
model reflects the complexity of the immune system 
responses. This variability is similar in MS patients. 
Accordingly, each animal or patient must be 
considered as a single immune entity.  
Moreover, current therapies against MS elicit a 
large number of well-reported side effects [1]. The side 
effects of IFNβ are injection-site reaction, flu-like 
symptoms, depression, elevated liver enzymes, and 
leukopenia [1], while those for glatiramer acetate are 
injection-site reaction, postinjection systemic reactions, 
and chest tightness or pain and lymphadenopathy [1]. 
However, to date no side effects have been reported 
for the new potential drug addressed here (GEMSP), 
either in an open clinical trial or in experimental 
animals. This is because GEMSP does not elicit either 
biological, haematological, or hepatic side effects [8]. 
Finally, we are currently unaware of whether the effect 
of GEMSP on leukocyte infiltration is due to the fact 
that the blood-brain barrier has been repaired and/or Int. J. Biol. Sci. 2008, 4 
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whether this new drug candidate might diminish the 
effect of immune mediators or have some 
immunomodulatory function. This aspect should be 
addressed in future studies.  
GEMSP inside motoneurons 
Our findings show that some components of 
GEMSP cross the blood-brain barrier and that the drug 
is stored inside the motoneurons of the ventral horn of 
the spinal cord. This suggests that GEMSP could enter 
the motoneurons by means of pinocytosis or 
endocytosis, since it is well known that PL (to which 
the methionine is conjugated in GEMSP) is introduced 
into the cytosol by those mechanisms [21]. It therefore 
seems that the localization of the component 
(conjugated methionine) of GEMSP inside the 
motoneurons could be explained in terms of PL 
transport into the cell, although specific receptors for 
some of the components of the GEMSP might be 
involved in the incorporation of such components into 
the motoneurons. Moreover, motoneurons are well 
k n o w n  t o  b e  r i c h  i n  m e t h ionine residues, although 
conjugated methionine cannot be used for the 
synthesis of peptides because here it was conjugated to 
PL via glutaraldehyde. At present, we are unaware of 
the physiological consequences of the morphological 
findings observed here. Nevertheless, it is known that 
vitamins and thiols (glutathione, cysteine, 
methionine…) are involved in the neutralization of 
free radicals, inhibiting apoptotic mechanisms [22-24]. 
This could be one of the possible actions of GEMSP on 
motoneurons. Previous pharmacokinetic studies 
carried out by our group have shown that the 
components of the GEMSP can be detected in serum at 
least 24 h after a single subcutaneous injection of 
GEMSP. Moreover, a serum concentration peak of the 
components of GEMSP was found two hours after the 
administration of GEMSP. Despite this, we are unable 
to explain why GEMSP was only found in the spinal 
cord and not in the brain of the animals of the group 1. 
I n  t h i s  s e n s e ,  i t  i s  p o s s i b l e  t h a t  G E M S P  c o u l d  b e  
metabolized faster in the brain than in the spinal cord. 
The antibodies used here for the localization of 
one component (methionine-G-PL) of GEMSP were 
generated with an immunogen containing a  carrier 
protein (bovine serum albumin, BSA) other than PL, 
since it is known that PL is a non-immunogenic 
peptide (see patent numbers of GEMSP: 6114388 (USA) 
and 792167 (EU)). However, it should be remarked 
that according to ELISA, the anti-conjugated 
methionine antibodies recognized both the methionine 
conjugated via glutaraldehyde to BSA and that 
conjugated to PL. These data were confirmed when the 
preabsorption of the diluted antibody (anti-conjugated 
methionine) was carried out with methionine-G-BSA 
or with methionine-G-PL (a component of GEMSP). In 
both cases, the immunoreactivity observed in the 
motoneurons disappeared. This means that the 
antibody specifically recognizes the same part of the 
antigen (methionine-G-first lysine residue), since this 
lysine residue is present in both BSA and PL. As has 
been previously demonstrated, it is known that free 
methionine is not recognized by the antibody used in 
the present study (anti-conjugated methionine) [25], 
and the same is the case of other molecules (e.g., 
acetylcholine, tryptophan, 5-hydroxytryptophan, 
5-hydroxytryptamine, 5-methoxytryptophan and 
5-methoxytryptamine) conjugated in the same way as 
the methionine studied here [26, 27]. It is also known 
that paraformaldehyde does not fix free molecules 
such as amino acids and their derivatives quickly, 
unlike glutaraldehyde. Here, we perfused the animals 
with paraformaldehyde, and hence the free 
methionine was not fixed, whereas the methionine 
(non-free)-G-PL was specifically recognized by the 
antibodies directed against the conjugated methionine 
via glutaraldehyde. It is also known that when 
methionine is conjugated via other coupling agents 
(e.g., glutaric anhydride) it is not recognized by these 
antibodies  (see  [25]). Using paraformaldehyde, 
methionine-G-PL was fixed to the tissue by the free 
amines of the PL, this being due to the free amine 
groups not linked to the methionine (more than 50% of 
the residues of PL are still free after linkage to 
methionine via glutaraldehyde). Additionally, the 
competition experiments carried out with ELISA 
showed that the antibodies were specific to conjugated 
methionine and did not recognize other molecules (see 
Table 2). All the above data indicate that the observed 
immunoreactivity is specific to one component 
(methionine-G-PL) of the GEMSP. 
It should be noted that methionine-G-BSA cannot 
be included as a component of GEMSP: first, because 
of the animal origin of BSA (this compound could 
induce possible unexpected side effects (e.g., allergy...) 
that cannot be controlled) and second, because if BSA 
is used antibody production against the drug will be 
induced and this could neutralize the therapy and 
produce important side effects. Accordingly, we used 
PL instead of BSA in the development of this potential 
therapy (GEMSP).   
Available Data on GEMSP Toxicity  
The toxicity of GEMSP has been tested by 
Gemacbio (Cenon, France) as well as by an 
independent laboratory (EVIC, France) (see [8]). The 
results reveal zero mortality in animals after a single 
intravenous dose of 10 mg/kg (LD0 and LD50 >10 
mg/kg) (see [8]). The quantities used in the toxicity 
study were lower than those used in the present study, Int. J. Biol. Sci. 2008, 4 
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but here the product was administered 
subcutaneously. 
Plausible Therapeutic Window of GEMSP in MS 
patients  
The available clinical data show that the key 
inclusion criteria for the therapeutic window in 
humans in an open clinical trial would be: a) disability, 
as evaluated by the expanded disability status scale 
(EDSS) in patients with Secondary Progressive 
Multiple Sclerosis (SPMS) (EDSS 3-6.5); b) a minimum 
1-point increase in EDSS during the 24 months prior to 
the beginning of the clinical trial. The results of the 
statistical analysis obtained at six months of treatment 
with low doses of GEMSP (0.75 mg/day) were 
conclusive: 55% of the patients maintained a stable 
EDSS value and 18% of patients had decreased EDSS 
values [8], instead of a normal progression of 0.25 
points on the mean EDSS scale. These data allow us to 
conclude that GEMSP could be an effective new drug 
candidate for MS treatment as shown in the acute EAE 
model [8] and in the present study carried out with a 
chronic EAE model.  
In sum, the activity of GEMSP against leukocyte 
infiltration previously shown in the acute EAE model 
has been validated in the chronic EAE model. 
Moreover, we found that there was no correlation 
between the degree of EAE and leukocyte infiltration. 
Our results demonstrate the presence of GEMSP 
(methionine-G-PL)  in the motoneurons of the spinal 
cord, and the drug appears to be a good candidate for 
the prevention and treatment of MS, since GEMSP 
completely abolished the crises and the clinical scores 
in a chronic EAE model. The finding of an anatomical 
location of GEMSP in the spinal cord opens new lines 
of research (electron microscopy, electrophysiology, 
brain slices…) to gain further insight into the action of 
the drug on motoneurons (for example, it is quite 
important to know whether GEMSP acts on gene 
regulation, and specifically on the expression of 
growth factors; to determine the possible action of 
GEMSP, by neutralizing free radicals, on the inhibition 
of apoptotic mechanisms...).  Moreover, a previous 
work [8] has shown that some amino acids and their 
derivatives (methionine, cysteine, taurine and 
5-methoxy-tryptamine) play an important role as 
radical scavengers and as neuroprotective 
components. These molecules, including methionine, 
are linked to PL and are components of GEMSP. In the 
future, other possible actions of the GEMSP, such as 
anti-oxidant and anti-radical stresses and axonal 
protection, should be investigated in depth, but the 
data reported here do suggest that GEMSP may be 
considered as a new potential drug candidate for the 
treatment of MS. 
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